Skip to main content
xMedica

NCT07624305ClinicalTrials.gov

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered…

Phase 32,800 participants sought478 sites27 countries

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-06-03; recorded start 2026-09-01
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 45 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,800 participants (target), run at 478 sites, across 27 countries.

How this score is built
  • Enrolment34/40

    2,800 participants (target)

  • Site count19/25

    45 sites

  • Country count12/15

    8 countries

  • Planned duration9/10

    Planned over about 47 months

  • Sponsor scale10/10

    AstraZeneca has led 999 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.

This is a Phase III, multicentre, randomised, double-blind, double-dummy, parallel-group, active-controlled, event-driven study in participants with CKD Stage 3b and 4. The purpose of this study is to determine if balcinrenone/dapagliflozin, compared with dapagliflozin, administered as a capsule once daily on a background of standard of care (SoC) therapy, reduces the risk of CV death, death from kidney failure, kidney failure, sustained ≥ 50% decline from baseline in eGFR, and HF events in adults with CKD Stage 3b and 4. The study will also assess safety and tolerability of balcinrenone/dapagliflozin. Eligible patients will randomly be assigned with a 1:1 ratio to receive once daily administration of one capsule and one tablet of one of the following treatments: 1. Balcinrenone/dapagliflozin 15 mg/10 mg capsule and matching placebo for dapagliflozin 10 mg tablet 2. Dapagliflozin 10 mg tablet and matching placebo for balcinrenone/dapagliflozin capsule The study will be conducted at approximately 550 sites in approximately 30 countries, globally.

Conditions

  • Renal Insufficiency, Chronic

Eligibility

Eligibility
SexAll
Ages18 Years – 99 Years
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of CKD and at least one of the following: 1. eGFR ≥ 15 to \< 45 mL/min/1.73 m2 AND: UACR ≥ 30 mg/g (central laboratory) or UACR ≥ 100 mg/g (local laboratory ) or UPCR ≥ 200 mg/g (local laboratory). 2. eGFR ≥ 15 to \< 30 mL/min/1.73 m2 and UACR \< 30 mg/g (local or central laboratory UACR value). * Serum/plasma K+ ≤ 5.0 mmol/L * Maximum tolerated dose of an ACEi or an ARB, unless contraindicated or not tolerated. The dose should be stable for at least 4 weeks before screening. Exclusion Criteria: * Recent (within 90 days prior to screening) or ongoing dialysis, or likely to require dialysis within 3 months following randomisation * UACR ≥ 5000 mg/g or UPCR ≥ 7000 mg/g at screening. * SBP \> 180 mmHg or DBP \> 110 mmHg at screening. * SBP \< 90 mmHg at screening. * HbA1c \> 9% at screening * T1DM, except: 1. For US only: patients with T1DM treated with SGLT2i for at least 4 months prior to screening, without DKA during that period, and who have experience with ketone monitoring are eligible. 2. For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months prior to Screening, without DKA during the period of dapagliflozin treatment are eligible for inclusion. * Autosomal dominant polycystic kidney disease. * Major cardiac or valvular surgery, acute coronary syndrome (myocardial infarction or unstable angina), stroke, transient ischaemic attack within 12 weeks prior to screening. * Severe hepatic impairment (Child-Pugh Class C). * Adrenal insufficiency. * Clinically significant acute kidney injury within 12 weeks prior to the screening. * New York Heart Association functional HF class IV at screening, or hospitalisation for heart failure within 4 weeks prior to screening. * Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months) prior to screening. * Solid organ or bone marrow transplant or a plan for transplant within 6 months following randomisation. * Any use of the following medications and supplements: 1. MRAs 2. Aldosterone analogues 3. Aldosterone synthase inhibitors 4. Any use of potassium binders within 2 weeks prior to screening. Use is allowed after randomisation. 5. Strong or moderate inducers or inhibitors of CYP3A4, prohibited at least one week prior to randomisation

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhasePhase 3
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingQUADRUPLE (4)
Enrolment2,800 participants sought

Sponsor and collaborators

  • AstraZeneca Sponsor

Arms and interventions

  • Balcinrenone/dapagliflozinEXPERIMENTAL

    Patient receives once daily 1 capsule balcinrenone 15 mg and dapagliflozin 10 mg and 1 placebo tablet matching dapagliflozin.

  • DapagliflozinACTIVE_COMPARATOR

    Patient receives once daily 1 placebo capsule matching balcinrenone and dapagliflozin and 1 tablet dapagliflozin 10 mg.

Interventions

  • Drug Balcinrenone/dapagliflozin

    balcinrenone/dapagliflozin 15 mg/10 mg

  • Drug Dapagliflozin

    dapagliflozin 10 mg

  • Drug Placebo matching Dapagliflozin

    matching placebo for dapagliflozin 10 mg

  • Drug Placebo matching balcinrenone/dapagliflozin

    matching placebo for balcinrenone/dapagliflozin

Outcome measures

  1. Primary outcome

    Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event

    Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure * Initiation of maintenance dialysis or * Kidney transplantation * Sustained ≥ 50% decline from baseline in eGFR * HF with or without hospitalisation

    Time frame Up to 46 months.

  2. Secondary outcome

    Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure and sustained 50% or greater decline in eGFR.

    Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure: * Initiation of maintenance dialysis or * Kidney transplantation Sustained ≥ 50% decline from baseline in eGFR

    Time frame Up to 46 months.

  3. Secondary outcome

    Change in urinary albumin to creatinine ratio to Week 24

    Change from baseline to Week 24 in urinary albumin to creatinine ratio

    Time frame Baseline to Week 24

  4. Secondary outcome

    Time to first occurrence of cardiovascular death or heart failure event.

    Time from randomization to first occurrence of any of the components of the composite: * CV death * HF with or without hospitalisation

    Time frame Up to 46 months.

  5. Secondary outcome

    Time to cardiovascular death

    Time from randomization to cardiovascular death.

    Time frame Up to 46 months.

  6. Secondary outcome

    Time to death from any cause

    Time from randomization to death from any cause.

    Time frame Up to 46 months.

Dates

Dates
Start dateSeptember 1, 2026 (actual)
Primary completionJuly 1, 2030 (estimated)
CompletionJuly 1, 2030 (estimated)
First postedJune 3, 2026 (actual)
Last updatedSeptember 24, 2026
Results postedNot stated in the registry record
Status last verifiedSeptember 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

33 sites are recruiting

Argentina

Argentina
FacilityCityState or regionStatus
Research SiteCABANot yet recruiting
Research SiteCapital FederalNot yet recruiting
Research SiteCiudad de Buenos AiresNot yet recruiting
Research SiteLa PlataNot yet recruiting
Research SiteLanús EsteNot yet recruiting
Research SiteMar del PlataNot yet recruiting
Research SiteRosarioNot yet recruiting
Research SiteRosarioNot yet recruiting
Research SiteRosarioNot yet recruiting
Research SiteSan NicolásNot yet recruiting
Research SiteSanta FeNot yet recruiting
Research SiteSanta FeNot yet recruiting

Austria

Austria
FacilityCityState or regionStatus
Research SiteFeldkirchNot yet recruiting
Research SiteInnsbruckNot yet recruiting
Research SiteLinzNot yet recruiting
Research SiteSankt PöltenNot yet recruiting
Research SiteViennaNot yet recruiting
Research SiteViennaNot yet recruiting
Research SiteViennaNot yet recruiting
Research SiteViennaNot yet recruiting
Research SiteWelsNot yet recruiting
Research SiteWiener NeustadtNot yet recruiting

Brazil

Brazil
FacilityCityState or regionStatus
Research SiteBarretosNot yet recruiting
Research SiteBelo HorizonteNot yet recruiting
Research SiteBelo HorizonteNot yet recruiting
Research SiteBelémNot yet recruiting
Research SiteCampinasNot yet recruiting
Research SiteGoiâniaNot yet recruiting
Research SiteNatalNot yet recruiting
Research SiteRecifeNot yet recruiting
Research SiteSão Caetano do SulNot yet recruiting
Research SiteSão José do Rio PretoNot yet recruiting
Research SiteSão José dos CamposNot yet recruiting
Research SiteSão PauloNot yet recruiting
Research SiteSão PauloNot yet recruiting
Research SiteSão PauloNot yet recruiting
Research SiteSão PauloNot yet recruiting

Bulgaria

Bulgaria
FacilityCityState or regionStatus
Research SiteBlagoevgradNot yet recruiting
Research SiteNova ZagoraNot yet recruiting
Research SitePlevenNot yet recruiting
Research SitePlovdivNot yet recruiting
Research SiteSandanskiNot yet recruiting
Research SiteSevlievoNot yet recruiting
Research SiteSofiaNot yet recruiting
Research SiteSofiaNot yet recruiting
Research SiteSofiaNot yet recruiting
Research SiteStara ZagoraNot yet recruiting
Research SiteVarnaNot yet recruiting

Canada

Canada
FacilityCityState or regionStatus
Research SiteBramptonOntarioNot yet recruiting
Research SiteCalgaryAlbertaWithdrawn

428 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

  1. September 24, 2026

    Status changed

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  2. September 24, 2026

    Recruitment opened

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  3. September 24, 2026

    Site added

    433 sites added (478 total)

    45478